Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 1
2010 2
2011 5
2012 2
2014 2
2018 2
2021 1
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Results by year
Filters applied: . Clear all
Page 1
Optimizing atoh1-induced vestibular hair cell regeneration.
Staecker H, Schlecker C, Kraft S, Praetorius M, Hsu C, Brough DE. Staecker H, et al. Among authors: schlecker c. Laryngoscope. 2014 Oct;124 Suppl 5(Suppl 5):S1-S12. doi: 10.1002/lary.24775. Epub 2014 Jun 17. Laryngoscope. 2014. PMID: 24938696 Free PMC article.
The pharmacogenetic background of hepatitis C treatment.
Schlecker C, Ultsch A, Geisslinger G, Lötsch J. Schlecker C, et al. Mutat Res Rev Mutat Res. 2012 Jul-Sep;751(1):36-48. doi: 10.1016/j.mrrev.2012.02.001. Epub 2012 Mar 3. Mutat Res Rev Mutat Res. 2012. PMID: 22409946
Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies.
Rosenbrock H, Desch M, Kleiner O, Dorner-Ciossek C, Schmid B, Keller S, Schlecker C, Moschetti V, Goetz S, Liesenfeld KH, Fillon G, Giovannini R, Ramael S, Wunderlich G, Wind S. Rosenbrock H, et al. Among authors: schlecker c. Clin Transl Sci. 2018 Nov;11(6):616-623. doi: 10.1111/cts.12578. Epub 2018 Aug 23. Clin Transl Sci. 2018. PMID: 30136756 Free PMC article. Clinical Trial.
The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [14C]-BI 425809 in Healthy Males.
Burkard U, Desch M, Shatillo Y, Wunderlich G, Mack SR, Schlecker C, Teitelbaum AM, Liu P, Chan TS. Burkard U, et al. Among authors: schlecker c. Clin Drug Investig. 2022 Jan;42(1):87-99. doi: 10.1007/s40261-021-01111-9. Epub 2021 Dec 22. Clin Drug Investig. 2022. PMID: 34936055 Free PMC article. Clinical Trial.
Correction to: The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [14C]‑BI 425809 in Healthy Males.
Burkard U, Desch M, Shatillo Y, Wunderlich G, Mack SR, Schlecker C, Teitelbaum AM, Liu P, Chan TS. Burkard U, et al. Among authors: schlecker c. Clin Drug Investig. 2022 Apr;42(4):375. doi: 10.1007/s40261-022-01134-w. Clin Drug Investig. 2022. PMID: 35286627 Free PMC article. No abstract available.
Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics.
Moschetti V, Schlecker C, Wind S, Goetz S, Schmitt H, Schultz A, Liesenfeld KH, Wunderlich G, Desch M. Moschetti V, et al. Among authors: schlecker c. Clin Drug Investig. 2018 Aug;38(8):737-750. doi: 10.1007/s40261-018-0660-2. Clin Drug Investig. 2018. PMID: 29846887 Free PMC article. Clinical Trial.
16 results